Governor Kathleen Sebelius Nominated for Secretary of HHS - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Governor Kathleen Sebelius Nominated for Secretary of HHS


ePT--the Electronic Newsletter of Pharmaceutical Technology

On Mar. 2, 2009, President Obama nominated Kansas Governor Kathleen Sebelius as his new Secretary of Health and Human Services (HHS). Sebelius, who has served as governor of Kansas since 2003, was Kansas’ Insurance Commissioner from 1994-2002. Sebelius, a Democrat governor in a predominately Republican state, is expected to help facilitate bipartisan healthcare reform. “As Secretary of Health and Human Services, Sebelius will work with Democrats and Republicans alike to cut costs, expand access, and improve the quality of healthcare for all Americans,” a White House press release states. Her nomination awaits Senate approval.

President Obama also appointed Nancy-Ann DeParle Counselor to the President and Director of the White House Office for Health Reform. DeParle was previously commissioner of Tennessee’s Department of Human Services. According to the White House press release, DeParle handled budget matters for federal healthcare programs during the Clinton administration and managed Medicare and Medicaid.

Obama stated in the release that, “Healthcare reform that reduces costs while expanding coverage is no longer just a dream we hope to achieve—it’s a necessity we have to achieve. And today, I am proud to announce key members of my team who will be critical to that effort: Kansas Governor Kathleen Sebelius for my Secretary of Health and Human Services and Nancy-Ann DeParle as Director of the White House Office for Health Reform.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here